Moderna

Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.

Moderna is seeking to invalidate two patents belonging to Arbutus Biopharma that deal with drug-delivery technology.

International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.

Moderna

Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).